MedTrace Logo

Pioglitazone in Psoriasis- A Clinical and Molecular Study.

NCT01133561 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-02-23

No results posted yet for this study

Summary

The study will assess the effectiveness of Pioglitazone on cellular and clinical levels in terms of improvement of both skin and systemic manifestations of psoriasis.

The investigators assume that pioglitazone (one of thiazolidinediones readily available in Egypt), can regulate keratinocytes' disordered proliferation observed in psoriasis, in addition to improving the insulin resistance in peripheral tissues observed in many psoriatic patients and causing metabolic syndrome. This will allow to give a safer therapy than the available ones for psoriasis and to treat the patient in a more global perspective.

Conditions

Interventions

DRUG

actozone A

pioglitazone 30 mg tablet , once daily dose for 10 weeks

DRUG

actozone B

one tablet of vehicle without active ingredient pioglitazone

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Principal Investigators

  • Manal AW Bosseila, MD · Cairo University-Dermatology department

  • Mona RE Abdel Halim, MD · Cairo university- Dermatology department

  • Mohamed I Sheta, MD · Cairo university- Internal medicine department

  • Olfat G Shaker, MD · Cairo University- Biochemistry department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-07-31
Completion
2010-08-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133561 on ClinicalTrials.gov